Gannet BioChem Unveils New Leadership in Wake of Ampersand Acquisition
Company - People | Mar 11, 2025 | Ampersand Capital Partners
Gannet BioChem, a prominent specialty chemical CDMO, has announced significant leadership changes following its acquisition by Ampersand Capital Partners. Nicholas Shackley has been named CEO, bringing with him extensive experience in pharmaceuticals and chemical manufacturing. Chris Edwards will serve as CFO, while long-standing leader Dr. Tony Sander has assumed the role of COO. Shackley's previous roles included senior executive positions with Lupin Manufacturing Solutions and other major firms where he focused on expanding market share and strategic initiatives. The new leadership aims to harness innovation and growth, with Gannet BioChem poised to showcase its capabilities at the upcoming DCAT 2025. The company specializes in polyethylene glycol (PEG) reagents, vital for biopharmaceutical and therapeutic products, and operates a state-of-the-art facility in Huntsville, Alabama.
Sectors
- Biopharmaceutical Manufacturing
- Private Equity
Geography
- United States – Gannet BioChem's operations are based in Huntsville, Alabama, where its FDA-inspected facility is located.
- Netherlands – Ampersand Capital Partners operates with offices in Amsterdam, Netherlands, suggesting a broader geographic interest.
Industry
- Biopharmaceutical Manufacturing – Gannet BioChem is involved in the development, scaling, and manufacturing of polyethylene glycol (PEG) reagents, essential in biopharmaceutical and therapeutic products.
- Private Equity – Ampersand Capital Partners, a private equity firm, acquired Gannet BioChem, facilitating the leadership transition and supporting healthcare sector growth.
Financials
- $3 billion – Assets under management by Ampersand Capital Partners.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Gannet BioChem | Target Company | Company | A specialty CDMO specializing in PEG reagent manufacturing for biopharmaceutical products. |
| Ampersand Capital Partners | Bidding Company | Company | A middle-market private equity firm focused on healthcare sector investments. |
| Nicholas Shackley | CEO | Person | Newly appointed CEO of Gannet BioChem with extensive experience in pharmaceuticals. |
| Chris Edwards | CFO | Person | Appointed CFO of Gannet BioChem, previously held financial roles at Solesis and other major firms. |
| Dr. Tony Sander | COO | Person | Longtime leader at Gannet BioChem with over 30 years of experience in chemical manufacturing. |
| Melanie Fan | Principal at Ampersand | Person | Principal at Ampersand Capital Partners, made a statement about the leadership changes. |